Key result
Rivaroxaban linked to ~26% lower 30-day readmission risk vs. apixaban in pulmonary embolism.
Why the study?
Hospital readmission after pulmonary embolism is common, but limited evidence exists comparing readmission risk between rivaroxaban and apixaban.
Does rivaroxaban reduce all-cause hospital readmission in adult patients with pulmonary embolism compared to apixaban?
Cohort (n=2,893)
Yes
Does rivaroxaban reduce all-cause hospital readmission in adult patients with pulmonary embolism compared to apixaban?
In a real-world cohort of patients with pulmonary embolism, rivaroxaban was associated with a significantly lower risk of 30-, 60-, and 90-day all-cause hospital readmission compared to apixaban.
Answers are grounded in this paper and cite their sources.
May support rivaroxaban preference to reduce PE readmissions; hypothesis-generating and leaves open need for RCT confirmation.
Background Although hospital readmission after pulmonary embolism (PE) is common, there is limited evidence on the comparative risk of readmission between rivaroxaban and apixaban. This study compared the real-world risk of all-cause hospital readmission among patients with PE treated with rivaroxaban or apixaban. Methods This retrospective study used data from Mass General Brigham's Research Patient Data Registry (01/2013-05/2023) to identify adult patients newly initiated on rivaroxaban or apixaban during a PE-related hospitalization (discharge = index). Patients with venous thromboembolism in the 3 months prior to the index PE hospitalization were excluded. All-cause hospital readmissions at 30, 60, and 90 days post-index were assessed using Kaplan-Meier analysis and were compared between cohorts using hazard ratios (HRs), 95% confidence intervals (CIs), and p-values from Cox proportional hazards regression models. Inverse probability of treatment weighting was used to adjust for baseline confounding. Results In total, 686 rivaroxaban (mean age: 59.5; female: 50.1; Quan-Charlson comorbidity index: 1.51) and 2207 apixaban (mean age: 60.6; female: 50.8; Quan-CCI: 1.58) initiators were included. Rivaroxaban was associated with a 26% lower risk of all-cause hospital readmission at 30 days post-index (12.3% vs 16.5%; HR [95% CI]: 0.74 [0.58, 0.94]; P = .012). Risk of hospital readmission was also significantly lower at 60 days (17.0% vs 22.3%; HR [95% CI]: 0.74 [0.61, 0.91]; P = .004) and 90 days post-index (21.6% vs 25.6%; HR [95% CI]: 0.81 [0.68, 0.98]; P = .029). Conclusions Rivaroxaban was associated with significantly lower risk of all-cause hospital readmission within 90 days post-discharge from PE-related hospitalization than apixaban.
No takes yet. Share an insight, caveat, or question.
Ashton et al. (2025) conducted a cohort in Pulmonary Embolism (n=2,893). Rivaroxaban vs. Apixaban was evaluated on All-cause hospital readmission at 30 days post-discharge (HR 0.74, 95% CI 0.58, 0.94, p=.012). Rivaroxaban was associated with a 26% lower risk of all-cause hospital readmission at 30 days post-discharge compared to apixaban in patients with pulmonary embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: